Scholars@Duke

• Research
• 

  Selected Grants

  • Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens awarded by National Institutes of Health 2022 - 2027
  • Exploitation of a new targetable node in the AR signaling pathway in prostate cancer awarded by Department of Defense 2022 - 2025
  • Evaluation of SGK as a therapeutic target in models of breast and prostate cancer awarded by LQT Therapeutics 2021 - 2022
  • ER and LXR as mediators of the pathobiology of hypercholesterolemia awarded by National Institutes of Health 1997 - 2020
  • Hypercholesterolemia as a modifier of the tumor microenvironment in breast cancer awarded by Department of Defense 2016 - 2019
  • Evaluation of G1 antiestrogens in models of estrogen action awarded by G1 Therapeutics Inc. 2018 - 2019
  • Evaluation of G1T48 in models of estrogen action awarded by G1 Therapeutics Inc. 2017 - 2018
  • Optimization of ERalpa-LBD-based CAR-T switch awarded by Cell Design Labs, Inc 2017 - 2018
  • Evaluation of the SERD XR5-28 in models of estrogen action awarded by G1 Therapeutics Inc. 2016 - 2017
  • Evaluation of G1T38 and SERD XR5-28 in hormone refractory breast cancer awarded by G1 Therapeutics Inc. 2016 - 2017
  • Molecular Determinants of Androgen Receptor Pharmacology awarded by National Institutes of Health 2003 - 2013

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.